Solid Biosciences (SLDB)
(Delayed Data from NSDQ)
$8.77 USD
-0.34 (-3.73%)
Updated Apr 24, 2024 03:59 PM ET
After-Market: $8.77 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SLDB 8.77 -0.34(-3.73%)
Will SLDB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SLDB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLDB
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
SLDB: What are Zacks experts saying now?
Zacks Private Portfolio Services
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
Other News for SLDB
Edgewise gets EU orphan drug status for muscular dystrophy drug
Buy Solid Biosciences: Unpacking Its Main Value Driver
British billionaire fined $5M, sentenced to 3 years probation for insider trading
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy